Gemina Laboratories Ltd. Stock Analysis GLAB.CN

Gemina Laboratories Ltd. engages in the development of biotechnology in the In Vitro Diagnostics and human wellness monitoring market under the name “Gemina Labs.” Its products include LEGIO X, LEGIO XI, Respiratory Syncytial Virus, and Tuberculosis. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2021-08-10. The firm is a biosensor and binding technologies company with a transformative, patented, proprietary chemistry that powers testing platforms for a range of pathogens that affect human health and wellness. The firm operates in the in vitro diagnostics (IVD) and human wellness monitoring market under the name Gemina Labs. The company operates within a single segment, being the research, development and commercialization of in-vitro diagnostics. Its technologies include dual affinity binding mechanism, gold binding protein, cellulose binding protein and more surface binding proteins. Its products include LEGIO X, which is a COVID-19 rapid antigen test, and LEGIO XI, which is a multiplex device that can detect and distinguish between influenza types A and B with no cross reactivity. LEGIO products in development include respiratory syncytial virus and tuberculosis.